



**Testimony to the  
Senate Health and Human Services Committee**

**Thursday, March 26, 2025**

**IN SUPPORT OF SENATE BILL 2253**  
*“AN ACT RELATING TO INSURANCE - RESCRIPTION DRUG BENEFITS”*

**Offered by**  
Bill Murphy  
Director, Advocacy & Public Policy  
Epilepsy Foundation New England

Senator Melissa A. Murray, Chair  
Senator Pamela J. Lauria, Vice Chair  
Senator Lori Urso, Secretary  
Senator Peter A. Appollonio, Jr.  
Senator Gordon E. Rogers  
Senator Brian J. Thompson  
Senator Linda L. Ujifusa  
Senator Bridget Valverde  
Robin Dionne

Chair Murray and Members of the Senate Health and Human Services Committee:

On behalf of the Epilepsy Foundation New England, and the more than 11,100 individuals living with epilepsy in Rhode Island, we urge you to support Senate Bill 2253 regarding the application of cost-sharing amounts toward deductibles or out-of-pocket maximums.

We appreciate, and hope to build upon, the support this Committee gave the bill last year which passed the full Senate unanimously. We look forward to working together to make this bill the law in Rhode Island.

Everyone is well aware of the rising costs of healthcare and access to medications.

S 2253 would ensure that all people with high prescription drug costs have access to needed medications, even if they receive assistance to afford their drugs.

Many people living with chronic disorders, such as epilepsy, rely upon payment assistance programs to help cover the costs of what can often be very expensive medications.

Here at the Epilepsy Foundation, we too have a medication assistance program to help individuals cover the costs of their epilepsy medications. During the pandemic, and since, we have seen an increase in the number of requests and, in turn, have increased the funds allocated to help folks. The need is real; they simply **cannot** afford their medications. With financial uncertainty facing many of our citizens, placing additional constraints on their ability to pay or to have coverage delayed for their medications is simply wrong.

Issuers have instituted copay accumulator programs as a result of unfounded concerns that copayment reimbursements by prescription drug manufactures incentivize physicians to prescribe more expensive drugs when folks could be taking a generic. However, this is an inappropriate assumption, especially in relation to epilepsy. Epilepsy medications are not interchangeable, and treatment of epilepsy is highly individualized. And please keep in mind that not all drugs have a generic version. We feel that this claim is unfounded given that less than 1% of commercial pharmacy claims filled using cost-sharing assistance were for a brand medicine with a generic equivalent.

There is no “one size fits all” treatment option for epilepsy, and the response to medications can be different for each person. In addition, many people with epilepsy, especially those living with rare epilepsy syndromes, are on several meds for their seizures and accompanying co-morbidities. Needing several, high-cost medications can have an unbearable cumulative financial effect for these folks without this assistance.

This bill helps to assure that people can continue to afford needed, lifesaving medications by allowing co-pay assistance to count toward an individual’s out of pocket costs, deductibles, and cost sharing.

The assistance our Foundation, and other programs offer is real – and benefits those folks who most need it. A 2020 study showed that:

- On average, copay assistance lowered patients’ out-of-pocket cost on average by \$55/prescription; \$55 can make a substantial difference for an individual. And the savings only grow if a person is on more than one medication. For instance, close to 25% of people living with epilepsy are on one or more medication to control their seizures.
- Copay assistance helped those with worse insurance plans, lowering out-of-pocket spending by 44% among patients who were required to pay the most by their insurance company; and
- They noted that accumulator policies shift increased drug costs to patients – while insurers are allowed to double dip.

Contrary to opponents’ claims that not using accumulator adjustors will drive up premiums, studies show that premiums do not go up if this assistance benefits the patient.

Oftentimes, patients do not even know their insurer has an accumulator adjustor policy in place. I have heard of instances where one shows up at the pharmacy only to find out they have an exorbitant co-pay and simply leave without their medications because they cannot

650 Suffolk Street, #405 Lowell MA 01854 [www.epilepsynewengland.org](http://www.epilepsynewengland.org)

Our mission is to help people and families affected by epilepsy in New England.  
We are an independent 501 (c)(3) nonprofit organization with tax identification # 22-2505819

afford it...all unexpected to them.

Whether it is called an ***Out-of-Pocket Protection Program***, or as United Healthcare refers to it, Coupon ***Adjustment/Benefits Plan Protection Program*** the intent is the same. And the impact upon patients is the same. This would impact everyone differently, but without the protections in S 2253 it would often mean higher, unanticipated copays at the pharmacy because they are satisfying their deductible later than they used to, if at all.

Not passing S 2253 would translate to higher and unanticipated copays because deductibles would be satisfied later than they had been. This would undermine affordability, adherence to needed medications, and therefore, health outcomes. Patients should not be denied this assistance or punished for relying upon help to cover the costs of their medications. Only the insurance companies will benefit and see a savings....not the patient!

1 in 26 Americans will develop epilepsy at some point in their lifetime. Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions.

For most people living with epilepsy, anti-epileptic drugs (AEDs) are the most common and cost- effective treatment for controlling and/or reducing seizures, and they must have meaningful and timely access to physician-directed care and prescribed medications. To change, limit, or deny access to medications could be extremely dangerous.

Senate bill 2253 will, rightfully so, allow financial support from manufacturers, and assistance from the Foundation's own medication assistance program, to count towards an individual's deductible.

This bill allows peace of mind for many by preventing unpredictable changes to how a deductible is calculated by a health plan. Such changes in affordability could impact adherence rates. Individuals may abandon medications at the pharmacy counter or adjust their medication regimen by trying to make their refill last longer and jeopardize their health. People living with complex chronic conditions increasingly face a landscape that makes it difficult to afford the medications prescribed by their provider. Especially during these uncertain times, this bill recognizes the need for ensuring that people can afford to get the medications they need. Now is not the time to add yet more barriers.

To date, 21 states, DC and Puerto Rico have passed legislation that bans harmful accumulator policies. With your continued support we look forward to working together to make Rhode Island number 22!

Epilepsy Foundation New England urges you to support S 2253.

I am happy to answer any questions and can be reached at  
[wmurphy@epilepsynewengland.org](mailto:wmurphy@epilepsynewengland.org)

Respectfully submitted,  
Bill Murphy  
Director, Advocacy & Public Policy  
Epilepsy Foundation New England

650 Suffolk Street, #405 Lowell MA 01854 [www.epilepsynewengland.org](http://www.epilepsynewengland.org)

Our mission is to help people and families affected by epilepsy in New England.  
We are an independent 501 (c)(3) nonprofit organization with tax identification # 22-2505819